SNTI - Rasio utang marang kapitalisasi buku Senti Bio

Senti Biosciences, Inc. (SNTI) focuses on creating programmable gene circuits for the targeted elimination of tumors. A robust R&D foundation in synthetic biology provides significant leadership potential. Recession resilience is guaranteed by a sovereign drug development cycle. This debt-to-equity chart demonstrates current credit risk, where the 0.00 level captures the company's latest financial leverage values.

The total liabilities-to-equity ratio determines the issuer's dependence on borrowed funds and its resilience to default. The current value of 0.00 demonstrates the business's actual margin of safety. By analyzing the company's balance sheet financial leverage, an investor assesses the ability of Senti Biosciences, Inc. (SNTI) to finance complex biocomponent supply chains. Diversification of production bases reduces operational risks. The downward trend of this metric confirms the long-term financial stability of the capital.